Zuranolone, a new treatment for postpartum depression, has hit the market with promising results but faces challenges in insurance coverage. Many insurers have yet to establish clear guidelines for when they will cover the drug, potentially limiting its accessibility. Previous experiences with a similar drug, brexanolone, showed restrictive policies that hindered patient access. Advocates are concerned about the lack of coverage guidance for zuranolone and hope for more patient-friendly policies. Regulatory changes are expected to influence insurers in setting coverage criteria for zuranolone, with a focus on mental health parity laws. In the meantime, patients are encouraged to discuss zuranolone with their doctors.
Source link
A New $16,000 Postpartum Depression Drug Is Here. How Will Insurers Handle It?
